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1. Introduction 
Ectopic pregnancy is a major public health problem worldwide. The incidence of ectopic 
pregnancy (EP) has been increasing recently. Currently, approximately up to 2% of 
pregnancies are ectopic (CDC, 1995). It is a leading cause of mortality in the first trimester of 
pregnancy (Berger et al., 2003). Furthermore, it is an important cause of morbidity and a 
high percentage of these patients may become infertile. For all these reasons efforts should 
be made to perform an early diagnosis before the occurrence of rupture. However, there can 
be misdiagnosis because the clinical presentation of ectopic pregnancy can simulate a 
variety of other pelvic diseases. Therefore, the physician must keep a high index of 
suspicion. Diagnosis has improved with the evaluation of the levels of beta-human 
choriongonadotropin hormone (beta-hCG) and through transvaginal ultrasound. 
Consequently, ectopic pregnancies can often be diagnosed before the patient’s condition has 
deteriorated, which has changed the former clinical picture of a life-threatening disease into 
a more benign condition in frequently asymptomatic patients. As a result, early detection 
through non-invasive diagnosis makes it possible to perform conservative treatment, such 
as expectant management or medical treatment with methotrexate (MTX). 
Additionally, atypical localization of ectopic pregnancies is associated with greater 
morbidity. In these situations medical treatment with systemic MTX and in cases with 
embryonic cardiac activity treatment with direct injection of potassium chloride or MTX has 
been used effectively. Clinical treatment avoids surgeries such as hysterectomy that end up 
being required in great number of cases of unusual localization. 
In this chapter, it will be discussed aspects related to the conservative treatment of ectopic 
pregnancy, mainly clinical treatment with expectant management and medical treatment of 
methotrexate. The chapter will point out features of the selection criteria, methotrexate 
protocols, predictive factors of success and reproductive future. 
2. Expectant mangement 
Ectopic pregnancy is associated with life-threatening risk and is considered to be a 
dangerous disease. Fear of tubal rupture caused by the uncertainty of this clinical situation 
induces gynecologists to take rapid decisions to solve the problem. However, knowledge of 
this disease has demonstrated that patients present a broad spectrum of symptoms. Thus, 
ectopic pregnancy does not always end in tubal rupture. In some cases, even without 
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intervention ectopic pregnancies may progress to abortion from their tubal implantation 
with minimal bleeding or even be reabsorbed. The great challenge is to identify the cases in 
which intervention is unnecessary. 
2.1 History 
Lund (1955) was the first to describe expectant management in women with ectopic 
pregnancy. This retrospective study compared expectant management (119 cases) versus 
open surgery (85 patients). Women with a typical course of ectopic pregnancy and a positive 
pregnancy test without hemoperitoneum on admission formed the group of expectant 
management. These patients were hospitalized until the pregnancy test became negative 
and pain ceased, whereas the other group of women was operated. Surprisingly, expectant 
management was successful in 57% of women. In 20% an operation was carried out for signs 
of intra abdominal hemorrhage, while in 23% of women an operation was performed after a 
four weeks stay in the hospital with no signs of the disease becoming quiescent. 
All subsequent studies of expectant management selected patients with unruptured ectopic 
pregnancy with declining titers of beta-hCG. In 1982, Mashiach et al. observed and treated a 
series of five cases with tubal pregnancy diagnosed by laparoscopy with serum beta-hCG 
concentrations <250 mIU/mL or decreasing, based on the knowledge that the natural course 
of many early ectopic pregnancies will result in tubal abortion or reabsorption. Expectant 
management was successful in four patients (80%). 
Based on these works, some case series have been published describing expectant 
management in selected patients. 
2.2 Inclusion criteria 
As expectant management has been practiced based on the acknowledgement that the 
natural course of many early EPs is a self-limiting process. One important point is to select 
the best cases for this treatment.  
The inclusion criteria for expectant management are: hemodynamically stable patients, beta-
hCG < 1500 mUI/ml, decline of the titers of beta-hCG in an interval of 24/48h, extraovarian 
adnexal mass < 3.5cm without fetal cardiac activity (Table 1). The exclusion criteria are 
patients with a viable ectopic pregnancy, signs of tubal rupture and active intra abdominal 
bleeding. The main inclusion criterion is the decrease of the levels of beta-hCG in an interval 
of 24/48h, because it represents that the pregnancy is in regression (Elito et al., 2008).  
The maximum value of beta-hCG to adopt this management is controversial. The majority of 
studies recommend the treatment when the titers of beta-hCG is equal or less than 1500 
mIU/mL (Hajenius et al., 1995).  However, others perform the observation with beta-hCG > 
1500 mIU/mL (Lang et al., 1997). Elito and Camano (2006) demonstrated that the mean 
values of beta-hCG were 648.8 ± 754.7 mIU/ml in the expectant management compared to 
2642.7 ± 2315.1 mIU/mL in the methotrexate treatment. Another interesting observation in 
this study is the period of amenorrhea that was longer in the expectant management group  
(8.87 ± 1.71 weeks) compared to the MTX treatment (6.81 ± 1.88 weeks). Therefore, women 
diagnosed with ectopic pregnancy may be categorized into two groups: those with an early 
diagnosis, and those with a late diagnosis. Early diagnosis is characterized by a shorter time 
since the last menstrual period, serum beta-hCG levels increasing or maintained over 24 and 
48-hour intervals, higher beta-hCG levels, rapid growth, and higher probability of tubal 
rupture. For that reason, these cases require medical treatment with methotrexate or 
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surgery. Late diagnosis is characterized by a longer time since the last menstrual period, 
beta-hCG levels decreasing over 24 and 48-hour intervals, lower beta-hCG levels, a latent 
prolonged clinical course, and lower chance of tubal rupture. Consequently, these cases 
require expectant management.  
 
Expectant Management 
Hemodynamically stable patients 
Decline of the titers of beta-hCG < 15% in an interval of 24/48h  
Beta-hCG < 1,500 mUI/ml 
Extraovarian adnexal mass < 3.5 cm 
Adnexal mass without embryonic cardiac activity 
Desire of future fertility 
Informed consent obtained 
Table 1. Inclusion Criteria for Expectant Management (Elito et al, 2008) 
2.3 Follow-up 
Beta-hCG levels are followed up weekly to ensure that concentrations decline gradually until 
it becomes undetectable. Complete resolution of an ectopic pregnancy usually takes 20 days 
(range from 4 to 67 days). Kamrava et al. (1983) described that the serum clearance of beta-
hCG may take at least up to 24 days after surgery. The same time necessary to complete 
resolution of an ectopic pregnancy managed expectantly. When declining beta-hCG levels rise 
again, there is a diagnosis of a persistent ectopic pregnancy. Success rates in several studies 
vary between 47.7% and 100% (van Mello et al., 2009) (Table 2). Transvaginal ultrasound is not 
required as a routine during the period of declining beta-hCG levels. However, patients with 
severe pain or pain that is prolonged should be evaluated by transvaginal ultrasound and 
hematocrit. Although the ultrasound findings are not helpful in the majority of patients, it can 
be use to reassure patient and physician that there ectopic pregnancy has not ruptured. It is 
important to realize that cul-de-sac fluid is very common, and the amount of fluid may 
increase if a tubal abortion occurs. For this reason, a surgical intervention is not necessary 
unless the patient has a typical clinical presentation of tubal rupture.  
The period for the regression of the adnexal mass at ultrasound is approximately of 3 
months. During this period patients are asked not to become pregnant. When the tubal mass 
is not recognized at ultrasound the patient should be submitted to hysterosalpingography. 
 
Authors  Cases  Success 
Ylostalo et al, 1992 83 57 (68.7%) 
Korhonen et al, 1994 118 77 (65.3%) 
Cacciatore et al, 1995 71 49 (69%) 
Trio et al, 1995 67 49 (73.1%) 
Shalev et al, 1995 60 28 (47.7%) 
Lui et al, 1997 17 17 (100%) 
Han et al, 1999 70 69 (98.6%) 
Olofsson et al, 2001 17 14 (82.4%) 
Elson et al, 2004 107 75 (70.1%) 
Table 2. Results of Studies of Expectant Management for Tubal Pregnancy 
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2.4 Predictive factors of success 
The most commonly identified predictors of success of expectant management are beta-hCG 
levels decreasing over 24 and 48-hour intervals, lower initial beta-hCG levels, absence of 
gestational sac at ultrasound and longer time since the last menstrual period (Han et al, 
1999; Elito e Camano, 2006). The mean levels of beta-hCG in the cases with success of the 
expectant management was 374mUI/ml, however when there was a failure the mean value 
was of 741 mUI/ml. Élson et al. (2004) observed that the success rate of the expectant 
management was 88% when beta-hCG levels was less than 200 mUI/ml, on the other hand 
the failure occur in 75% of the cases with beta-hCG > 2000 mUI/ml. Whereas the prognosis 
for successful expectant management has been demonstrated repeatedly to correlate with 
the initial hCG level, no consensus on a threshold value that best predicts success or failure 
has been established. 
2.5 Randomized trials 
Only two randomized controlled trials have been published on expectant management for 
ectopic pregnancy (Egarter et al., 1991; Karhonen et al., 1996).  
Egarter et al. (1991) compared expectant management and local and systemic prostaglandins 
including 23 women with an unruptured ectopic pregnancy and a serum beta-hCG 
concentration <2,500 mIU/ml. This trial shows that expectant management was significantly 
less successful than prostaglandin therapy (RR 0.12, 95% CI 0.02 to 0.81). 
Karhonen et al. (1996) compared expectant management versus systemic methotrexate. In 
this double blind placebo controlled trial, expectant management was compared with oral 
methotrexate in a low dosage (2.5 mg/day during five days) in 60 hemodynamically stable 
women with a small tubal ectopic pregnancy (<4 cm) without fetal cardiac activity and a 
serum hCG concentration <5,000 mIU/ml. This study virtually represents a comparison 
between two placebo treatments as is demonstrated in similar success rates of 77% in both 
treatment groups (RR 1.0, 95% CI 0.76 to 1.3). The mean serum hCG concentrations were 
low, i.e., 211 mIU/ml (range 20 to 1,343 mIU/ml) in the expectant group and 395 mIU/ml 
(range 61 to 4,279 mIU/ml) in the methotrexate group. 
An evaluation of expectant management for tubal ectopic pregnancy cannot be adequately 
made with these trials. Recently, there is a well-designed trial that will evaluate expectant 
management in the treatment of ectopic pregnancy. In a double blinded setting, single dose 
intramuscular methotrexate is compared with placebo in selected women with an ectopic 
pregnancy and a serum hCG concentration < 1500 mIU/ml. Therefore, nowadays the 
efficacy of expectant management for tubal ectopic pregnancy cannot be adequately 
evaluated (Hajenius et al., 2007). 
2.6 Reproductive future 
The fertility of women managed expectantly for an unruptured ectopic pregnancy can be 
determined by hysterosalpingography (HSG) or a spontaneous pregnancy (Rantala e 
Mäkinen, 1997; Debby et al., 2000). In spite of the inconveniences and interpretation doubts, 
HSG is considered a good examination to evaluate the tube patency (Gladstein et al., 1997). 
Hysterosalpingography is an important diagnostic method after conservative treatment of 
an ectopic pregnancy (Mol et al., 1997). If HSG demonstrates tubal patency, there is a 
possibility of spontaneous pregnancy; and in cases revealing obstruction in both tubes; the 
treatment is fertilization in vitro. Hysterosalpingography usually is performed 3 months 
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after expectant management, when the adnexal mass usually disappears on ultrasound 
examination. 
Elito et al. (2005a) showed a patency rate of 78% in the ipsilateral tube in women managed 
expectantly, which was similar to the rates reported in other studies (Stovall et al., 1991; 
Debby et al., 2000). The patency rate of the contralateral tube was 92% in women managed 
expectantly, which is also similar to the rates in other reports (Stovall et al., 1991; Zohav et 
al., 1996; Mass et al., 1997). 
When clinical treatment is chosen for unruptured ectopic pregnancy and tubal patency is 
evaluated via HSG, doubts arise: Could the tubal obstruction precede the ectopic pregnancy, 
or could it be a consequence of the treatment? To answer this question the obstruction of the 
contralateral tube has to be determined. Elito et al. (2005a) demonstrated that it occurred in 8% 
of the women managed expectantly. These results suggest that some of the women probably 
had an obstruction of the contralateral tube before the ectopic pregnancy, probably caused by 
salpingitis. The obstruction rate of the ipsilateral tube was 22% in the expectant management. 
Comparing these rates with those for contralateral tube obstruction (8%) shows that the 
difference between the obstruction rates for the ipsilateral and contralateral tubes could be a 
consequence of the tubal pregnancy treatment. Thus, the contralateral tube may give a picture 
of the tubal status previous to the tubal pregnancy. The difference between the obstruction 
rates of the ipsilateral and the contralateral tubes after clinical treatment may demonstrate 
which women experience tubal obstruction as a sequel of the nonsurgical treatment. 
The spontaneous healing of EP should not harm the tube and should result in a good long-
term fertility outcome. However, normal radiologic findings show nothing about tubal 
function, since a disturbance can also be a cause for ectopic pregnancy. On the other hand, if 
the HSG demonstrates obstruction of the tubes, these results reduce the possibility of a 
spontaneous pregnancy and the patients should be offered in vitro fertilization. 
3. Medical treatment 
3.1 Systemic treatment 
Systemic methotrexate for the treatment of gestational trophoblastic disease has been used 
since 1956 (Li et al., 1956). MTX is a folic acid antagonist. Folic acid normally is reduced to 
tetrahydrofolate by the enzyme dihydrofolate reductase (DHFR), a step in the synthesis of 
DNA and RNA precursors. MTX inhibits DHFR, causing depletion of cofactors required for 
DNA and RNA synthesis. When multiple doses of MTX are used, side effects may occur, 
such as gastric distress, nausea, vomiting, ulcerative stomatitis, dizziness and some rare 
situations like severe neutropenia, reversible alopecia and pneumonitis.  Folinic acid is an 
antagonist to MTX that can help reduce side effects, particularly when multiple doses of 
MTX are used (Barnhart et al., 2001). Long-term follow-up of cases treated with MTX for 
gestational trophoblastic disease shows no increase in congenital malformation or 
spontaneous abortions. Therefore, none would be expected after treatment of ectopic 
pregnancy because a smaller dose is required and shorter treatment duration is used. 
3.1.1 History 
At first, methotrexate was used for the treatment of placenta left in situ after laparotomy for 
an abdominal pregnancy. Tanaka et al. (1982) during a laparotomy identified an advanced 
but unruptured interstitial pregnancy in a young patient. The authors to avoid the surgery 
that could compromise the reproductive future opted for a medical treatment with multiple 
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doses of intramuscular MTX. Since the beginning of the medical treatment of ectopic 
pregnancy, starting in 1982 with Tanaka et al., it has represented an important alternative 
for the treatment of ectopic pregnancy. Several authors have been studying this therapeutic 
treatment (Stovall et al., 1989; Elito et al., 1999a; Lipscomb et al., 2000). One important study 
to consider is that performed by Stovall et al. In 1989, it individualized the methotrexate 
dosage to improve patient compliance, to minimize side effects, and to reduce overall costs, 
which ultimately led to a single-dose regimen of 50 mg/m2 body surface area intramuscular 
without folinic acid.  
3.1.2 Selection criteria 
Selection criteria for the systemic treatment with MTX are: hemodynamic stability, 
extraovarian adnexal mass < 3.5cm, beta-hCG < 5000 mUI/ml, no severe or persistent 
abdominal pain, commitment to follow-up until the ectopic pregnancy has resolved, and 
desire of future pregnancy (Table 3). The exclusion criteria are: intrauterine pregnancy, 
presence of free fluid in peritoneal cavity, adnexal mass with embryonic cardiac activity 
detected by transvaginal ultrasonography, decline of more than 15% in the levels of beta-
hCG in an interval of 24 h prior to the treatment, hepatic dysfunction, blood dyscrasia, renal 
disease, evidence of immunodeficiency, sensitivity to MTX, active pulmonary or peptic ulcer 
disease and refusal to accept blood transfusion (Elito et al., 2008) (Table 4 and 5). 
Prior to the treatment, women should be screened with a complete blood count, liver 
function tests, serum creatinine and blood type and Rh (prescribe Rhogam if patient is Rh 
negative). Patients having a history of pulmonary disease should also have a chest x-ray 
(ASRM Practice Committee, 2008). 
 
- Hemodynamic stability 
- Extraovarian adnexal mass < 3.5cm  
- No severe or persistent abdominal pain 
- Desire of future pregnancy 
- Commitment to follow-up until the ectopic pregnancy has resolved  
- Informed consent obtained 
Table 3. Inclusion Criteria for Systemic Methotrexate (Elito et al, 2008; ASRM Practice 
Committee, 2008) 
 
- Intrauterine pregnancy 
- Evidence of immunodeficiency  
- Moderate to severe anemia  
- Leukopenia (Leukocytes < 2000 Cel/Mm3) 
- Thrombocytopenia (Platelets < 100000) 
- Sensitivity to Methotrexate 
- Active pulmonary disease  
- Active peptic ulcer disease  
- Clinically important hepatic or renal dysfunction 
- Breast feeding 
Table 4. Absolute Contraindications for Systemic Methotrexate (Elito et al, 2008; ASRM 
Practice Committee, 2008) 
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- Embryonic cardiac activity detected by transvaginal ultrasonography  
- High initial hCG concentration (>5,000mIU/mL) 
- Decline of the titers of beta-hCG > 15% in an interval of 24/48h  
- Refusal to accept blood transfusion  
- Inability to participate in follow-up  
Table 5. Relative Contraindications for Systemic Methotrexate (Elito et al, 2008; ASRM 
Practice Committee, 2008) 
3.1.3 Methotrexate protocols (single and multiple doses) 
There are two commonly used MTX treatment protocols: single dose and multiple doses 
(Barnhart, 2009). The single dose MTX treatment uses a 50mg/m2 intramuscular dose 
(Stovall et al., 1993; Elito et al., 1999a). Body surface area is calculated based in height and 
weight conformed Table 6. As a follow-up beta-hCG levels are tested on days 1, 4 and 7 after 
MTX injection. The protocol stipulated that any patient who did not have a 15% decline in 
the beta-hCG levels between days 4 and 7, should be given a second intramuscular dose of 
MTX (50mg/m2) one week after the first dose. Patients with declining beta-hCG levels > 
15% between days 4 and 7 were monitored weekly until the beta-hCG levels decreased 
below 5 mIU/ml. The term ‘‘single dose’’ is actually misleading. Whereas it describes the 
number of MTX injections planned, the treatment may include additional doses of MTX 
(maximum 3 doses) when the response is inadequate (Stovall et al., 1993; Barnhart, 2009). 
 
                Height 
cm 
Weight kg 
150 155 160 165 170 175 180 
40 1,30 1.33 1.37 1.40 1.43 1.46 1.49 
45 1.37 1.40 1.44 1.47 1.50 1.53 1.56 
50 1.43 1.47 1.50 1.54 1.57 1.60 1.64 
55 1.49 1.53 1.56 1.60 1.63 1.67 1.70 
60 1.55 1.59 1.62 1.66 1.70 1.73 1.77 
65 1.60 1,.64 1.68 1.72 1.75 1.79 1.83 
70 1.65 1.69 1.73 1.77 1.81 1.85 1.89 
75 1.70 1.74 1.78 1.82 1.86 1.90 1.94 
80 1.75 1.79 1.83 1.87 1.92 1.96 2.00 
85 1.80 1.84 1.88 1.92 1.97 2.01 2.05 
90 1.84 1.88 1.93 1.97 2.01 2.06 2.10 
Table 6. Calculation Body Surface Area (log BSA = 0.425 log W + 0.725 log H - 2.1436) (Du 
Bois, Du Bois, 1916). 
The multiple-dose protocol alternates 4 intramuscular doses of MTX (1mg/kg) with 4 
intramuscular doses of leucovorin (0,1 mg/kg). The patients are followed up with beta-hCG 
levels in the day of MTX injection. MTX is continued until beta-hCG falls by 15% from its 
peak concentration. Approximately 50% of patients will not require the full 8-day regimen 
(Pisarka et al., 1998). A meta-analysis of nonrandomized studies showed success rates of 
93% for multiple-dose treatment and 88% for single-dose therapy (Barnhart et al., 2003). The 
odds ratio for failure of single-dose therapy as compared with multiple-dose therapy was 
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2.0 after adjustment for the beta-hCG value and 4.8 after adjustment for the presence of fetal 
cardiac activity. As compared with the multiple-dose treatment, the single-dose protocol is 
more simple, commonly used, requires fewer visits and has fewer side effects. For all this 
reasons it should be the first option in cases of tubal pregnancy with levels of beta-hCG less 
than 5000 mIU/mL (Elito et al, 1999a). On the other hand, in cases of non-tubal pregnancy 
with high levels of beta-hCG more than 5000 mIU/mL, the best choice is the protocol of 
multiple-dose of MTX. 
Recently, an alternative protocol of MTX was described. In this protocol women received 2 
doses of methotrexate 50mg/m2 IM (Barnhart et al., 2007). The initial day of treatment was 
designated day 0. Patient returned on day 4 and received the second dose of MTX, and the 
beta-hCG level was measured. On day 7, the beta-hCG level was measured and compared 
with the level on day 4. If there was a decline of at least 15%, the treatment was considered 
successful. These patients were monitored weekly until the beta-hCG levels decreased 
below 5 mIU/ml. The protocol stipulated that any case who did not have a 15% decline in 
the beta-hCG levels between days 4 and 7, should be given a third intramuscular dose of 
MTX (50mg/m2) on day 7. Patients then returned on day 11 for another beta-hCG 
measurement. If the beta-hCG level declined by at least 15% between day 7 and 11, the 
treatment was deemed successful and weekly beta-hCG levels were verified until the results 
were negative. If not, a fourth dose of MTX was administered, and a beta-hCG level was 
checked on day 14. If the beta-hCG titers declined at least 15% between days 11 and 14, the 
treatment was considered successful. Otherwise, the patient was referred for surgical 
treatment. The two-dose regimen was designed to increase the likelihood of successful 
therapy without more visits than are required with a single-dose regimen, but it has not 
been directly compared with the other regimens. One important consideration is that two-
dose protocol should be indicated in cases with increase beta-hCG levels on day 4 after 
MTX.   
When the criteria for MTX treatment are fulfilled, treatment success rates are comparable to 
those achieved with conservative surgery (Hajenius et al., 1997). Numerous open-label 
studies have been published demonstrating the efficacy of MTX protocols. One review 
concluded that MTX treatment was successful in 78%–96% of selected patients (Lipscomb et 
al., 2000). 
3.1.4 Follow-up 
Patients with declining beta-hCG levels after MTX protocols (single or multiple-dose) are 
monitored weekly until the beta-hCG levels are negative. Elito et al. (1998) evaluated the 
interval of time for beta-hCG levels to become negative.  It took 15 days in 50% of the cases, 
15 to 30 days in 38.8% and more than 30 days in 11.2% of the cases. Complete resolution of 
an ectopic pregnancy usually takes between 2 and 3 weeks but can take as long as 6 to 8 
weeks when pre-treatment beta-hCG levels are in higher ranges (Elito et al, 1999a; Pisarka et 
al, 1998; Barnhart et al, 2003). When declining beta-hCG levels rise again, the diagnosis of a 
persistent trophoblastic tissue is made. Another important consideration is that the period 
for the regression of the tubal mass at ultrasound range from 3 to 6 months (Brown et al., 
1991). Elito et al. (1996) evaluated the period necessary for the complete resolution of the 
tubal mass at ultrasound and observed that it took more than 30 days in 62.5% of the cases. 
Therefore, serial ultrasonographic examinations after MTX treatment are unnecessary 
because ultrasonographic findings cannot demonstrate or predict treatment failure, unless 
evidence of recent tubal rupture is observed (Atri et al., 1992). 
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Although several treatment protocols have been developed, it is prudent to inform the 
patient some instructions for the follow-up after the systemic treatment with MTX. Patients 
should avoid: sexual intercourse until beta-hCG levels is negative, sun exposition to 
minimize the risk of dermatitis after MTX, alcohol use, nonsteroidal antiinflammatory drugs 
(in cases of pain prescribe acetaminophen), foods and multivitamins containing folic acid, 
become pregnant for at least 3 months (risk of teratogenicity).  
MTX is a safe treatment for an unruptured ectopic pregnancy. Life-threatening 
complications rarely have been reported with MTX (Isaacs et al., 1996). Approximately 40% 
of the patients feel pain between 3 and 7 days after MTX injection, but such pain normally 
resolves within 4 to 12 hours (Lipscomb et al., 1999). In cases of acute pain, it is important to 
rule out tubal rupture. Therefore, it is prudent to evaluate the patient’s vital signs and 
hematocrit, and if rupture is suspected, surgery should be performed. 
Signs of treatment failure or suspected rupture are indications to abandon medical 
treatment and to proceed with surgical treatment. Signs suggesting treatment failure or 
possible rupture include hemodynamic instability; increasing abdominal pain, regardless of 
trends in beta-hCG levels; and rapidly increasing beta-hCG concentrations after 
methotrexate treatment (ASRM Practice Committee, 2008). 
More commonly encountered treatment effects of MTX are increase in abdominal girth, 
increase in beta-hCG during initial therapy, vaginal bleeding or spotting and abdominal 
pain. The commonly side effects encountered are gastric distress, nausea and vomiting, 
stomatitis, dizziness, and other rare conditions such as severe neutropenia, reversible 
alopecia and pneumonitis (ASRM Practice Committee, 2008). 
 Sexual intercourse is allowed when the beta-hCG titer is negative. At this moment, patients 
are instructed to begin contraceptive methods until the regression of the adnexal mass at 
ultrasound. Patients are asked not to become pregnant for at least 3 months following the 
completion of treatment so that a hysterosalpingography can be performed. 
3.1.5 Predictive factors of success 
Although the failure of the treatment is not very high, when the tubal rupture occurs after a 
few days, a doubt arises: Would it not been better to perform a conservative surgery at the 
moment of the early diagnosis? To reduce the failure of the treatment several authors 
studied the predictive factors for the success of MTX treatment. Initial level of beta-hCG is 
one of the most important variables in the prediction of therapeutic response to MTX in 
patients with an ectopic pregnancy. The evolution of ectopic pregnancy depends on the 
degree of trophoblast invasion. Intense trophoblastic activity is more frequently associated 
with tubal rupture, while lesser activity is associated with a lower capacity of invasion and a 
greater likelihood of success with MTX treatment. The invasion of the trophoblastic tissue in 
patients with an ectopic pregnancy may be calculated from their serum beta-hCG level. In 
studies carried out in fallopian tubes affected by ectopic pregnancy, Natale et al. (2003) used 
histopathology to demonstrate that the concentration of beta-hCG was proportional to the 
degree of invasion of the tubal wall. Therefore, the higher is the beta-hCG level, the greater 
is the invasion of the trophoblast and the lesser the likelihood of therapeutic success with 
MTX (Menon et al., 2007). If the beta-hCG level is low, then the likelihood of therapeutic 
success is high; however, if beta-hCG is high, surgery would be preferable. Lipscomb et al. 
(1999) noted that the failure rate of single-dose treatment was 13% (6/45) for initial beta-
hCG values between 5,000 IU/L and 9,999 IU/L, 18% (4/22) for concentrations between 
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10,000 IU/L and 14,999 IU/L, and 32% (7/22) when beta-hCG values exceeded 15,000 IU/L. 
Elito et al. (1999) have reported failure rates of 62% when the initial beta-hCG concentration 
is over 5,000 IU/L. Systematic review combining all published data yields an odds ratio for 
failure of 5.45 (95% CI, 3.04–9.78) when the initial beta-hCG value above 5,000 IU/L 
compared with that observed when beta-hCG concentrations are below that threshold 
(Menon et al., 2007). Because the failure rate rises with the pre-treatment beta-hCG 
concentration, the single-dose MTX treatment regimen may be better reserved for patients 
with a relatively low initial beta-hCG level (Elito et al., 1999a; Barnhart et al., 2003; Potter et 
al., 2003). 
Attempting to improve the selection of patients for the medical treatment with MTX and 
reduce the likelihood of therapeutic failure, some authors evaluated an additional predictive 
variable: the increment in beta-hCG levels in the 48-h interval prior to administration of 
MTX (Dudley et al., 2004; da Costa Soares et al., 2008). The hypothesis is that the increase in 
beta-hCG levels in the 48-h period prior to treatment would represent a dynamic assessment 
of the degree of evolution of the ectopic trophoblastic tissue and, consequently, of its 
invasion and its probable response to treatment. Moreover, this variable is easily obtainable. 
Da Costa Soares et al. (2008) demonstrated that the average increment in beta-hCG levels in 
the 48-h period prior to treatment was greater in the patients with therapy failure when 
compared to the cases of therapeutic success (36.28 vs. 13.15%, respectively). One important 
point to consider is that when initial beta-hCG level is low but its increment in the 48-h 
period is high, this is indicative of an ectopic trophoblastic tissue with a high degree of 
invasion, and the risk of tubal rupture is high so surgical treatment is preferable. 
Furthermore, when beta-hCG is elevated, this parameter alone is sufficient to serve as a 
guideline for treatment, with good sensitivity and specificity. Nevertheless, in cases of early 
diagnosis (the ideal situation for non-surgical treatment), baseline beta-hCG is generally low 
and in this situation the increment in beta-hCG values in the 48-h period prior to treatment 
is of great importance, since depending on the evolution of beta-hCG, the predicted 
response to nonsurgical treatment may be better assessed, leading to increased specificity 
and sensibility with respect to the success of treatment. Dudley et al. (2004) reported that the 
increase in beta-hCG prior to diagnosis and the increase in beta-hCG following MTX 
therapy were more accurate predictors of tubal rupture than beta-hCG on the day of MTX 
therapy. These results suggest that the changes in beta-hCG prior to and following MTX 
administration represent independent risk factors for subsequent tubal rupture. 
Another important consideration is the aspect of the image at ultrasound (hematosalpinx, 
tubal ring and live embryo) (Figure 1 and 2). Elito et al. (1999a) observed better results with 
hematosalpinx image and worse results with live embryo. Several authors considered relative 
contraindications for systemic treatment with MTX the presence of embryonic cardiac activity 
detected by transvaginal ultrasonography (Lipscomb et al., 1999; Tawfiq et al., 2000). 
Other variables that may be predictive of therapeutic response to MTX in cases of ectopic 
pregnancy are: size and volume of the gestational mass (< 3.5 cm), absence of free peritoneal 
blood an endometrial thickness (<7mm) (Elito et al., 1999a; Soares et al., 2004; da Costa 
Soares et al., 2008). 
Therefore, factors that are associated with failure of medical management include initial 
beta-hCG values greater than 5000 mIU/mL, ultrasonographic detection of a moderate or 
large amount of free peritoneal fluid, the presence of embryonic cardiac activity, and a 
pretreatment increase in the serum hCG level of more than 50% over a 48-hour period 
(ASRM Practice Committee, 2008). 
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Fig. 1. Ultrasound of ectopic pregnancy with tubal ring: A) extra-uterine gestational sac with 
live embryo. B) gestational sac with absence of embryonic cardiac activity. C) gestational sac 
with yolk sac. D) gestational sac without yolk sac or fetal pole (Elito, Camano, 2010a). 
 
 
Fig. 2. Ultrasound of tubal pregnancy with hematosalpinx (Elito, Camano, 2010a). 
3.1.6 Reproductive future 
The fertility outcome of patients treated conservatively with MTX for unruptured EP can be 
evaluated by means of hysterosalpingography (HSG) or future pregnancy (Debby et al., 
A B 
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2000). Elito et al. (2005b) showed that 84% of the diseased tubes were pervious after MTX 
treatment for ectopic pregnancy by HSG, similar to the rates in other reports that 
demonstrated post-treatment hysterosalpingography documented tubal patency in 78% of 
cases (Lipscomb et al., 2000; Stovall et al., 1991). This high rate of radiologically normal 
tubes after clinical treatment proves that the spontaneous regression of EP does not result in 
an increased harm or damage to the tube – i.e. the risk of repeating EP is rather low. 
However, the radiologically normal findings show nothing about the tubal function, when a 
disturbance can also be a cause of EP. On the other hand, if the results of HSG demonstrate 
obstruction of the tubes, the possibility of a spontaneous pregnancy will be reduced and 
should be treated with in vitro fertilization. Elito et al. (2005b) showed that beta-hCG levels 
were directly related to the obstruction of the tube. The increase in beta-hCG levels was 
followed by an enhancement in tubal obstruction risk. The explanation for these events is 
probably that in patients with high level of beta-hCG there is more invasion of the 
trophoblast tissue at the serosa of the tube, which increases damage to the tube. 
The parameter considered most important for MTX treatment of unruptured EP is beta-
hCG. Several authors have demonstrated its importance (Elito et al., 1999a; Lipscomb et al., 
1999) and shown that the higher the level of beta-hCG, the lower the chances of successful 
treatment. Patients with indication for clinical treatment of EP usually have an important 
desire for future pregnancy. It is important to have a parameter, such as the levels of beta-
hCG, in order to predict the tube sequel. 
Lipscomb et al. (2000) demonstrated that 65% of patients who attempted subsequent 
pregnancies succeeded, and the incidence of recurrent ectopic pregnancy was a relatively 
low 13% (Stovall et al., 1989; Lipscomb et al., 2000). 
3.2 Local treatment 
Methotrexate can be administered locally in the tube. Efforts to attain maximal efficacy and 
minimize adverse effects of systemic MTX resulted in various protocols for local medical 
treatment administered into the gestational sac transvaginally under sonographic or under 
laparoscopic guidance. Drugs that have been used for local treatment are methotrexate 
1mg/kg (Feichtinger, Kemeter, 1987; Pansky, Bubowski, 1989; Fernandez et al., 1993), KCL, 
prostaglandins, and hyperosmolar glucose. 
3.2.1 History 
Feichtinger and Kemeter (1987) described the first case where local treatment with MTX was 
administered into the gestational sac transvaginally under sonographic. The authors used 
the same technique used for retrieval of the oocytes from the ovary using a transvaginal 
technique involving an ultrasound-guided needle utilized for in vitro fertilization. The 
gestational sac of the tubal pregnancy was puncture and injected 10 mg of MTX. The case 
was treated successful and without side effects.    
In 1989, Panski et al. presented another via to puncture the tubal pregnancy by laparoscopy. 
The gestational sac of 27 patients was punctured and injected 12,5 mg of MTX. The success 
rate was 88,9%, there are no side effects and tubal patency was 90.5%. 
3.2.2 Selection criteria 
Local treatment is indicated in ectopic pregnancies with embryonic heart activity, especially 
in cases of non-tubal ectopic pregnancies (Elito et al., 2008). One important point to consider 
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is that in cases of ectopic pregnancy with absence of embryonic cardiac activity, there is no 
reason to submit the patient to ultrasound-guided injection. In these cases the systemic 
treatment with MTX is considered to be the best choice. Although local injection appears to 
be relatively safe and as effective as systemic methotrexate, this approach requires an 
additional procedure and a certain degree of expertise and added cost. A further 
consideration is that the appropriate dose of local MTX is yet to be determined. Several 
doses of MTX have been described (Benifla et al., 1996; Sagiv et al., 2001; Lin et al., 2007). 
The most used is a dose of 1 mg/kg body weight and this is the dose selected for the study 
(Fernandez et al., 1993)). However, other doses including 100 mg single dose (Lin et al., 
2007), 50mg/m2 body surface (Lim et al., 2007) and an unadjusted dose of 12.5 mg have been 
used (Sagiv et al., 2001). Transvaginal ultrasound is the preferred mode for guidance and 
laparoscopic guidance has a limited role. The procedures were carried out under general 
anesthesia. The patient was placed in the lithotomy position. Methotrexate was injected 
under transvaginal ultrasound guidance, a 22-gauge, 15 cm Wallace needle was inserted via 
vaginal route into the embryonic heart and 1 ml (2 mEq/ml) KCL solution was injected. 
Following the cessation of embryonic cardiac activity, the tip of the needle was directed into 
the gestational sac and some amniotic fluid was aspirated. Then, a 1 mg/kg dose of MTX 
was injected into the gestational sac. The transvaginal administration of methotrexate under 
sonographic guidance requires visualization of an ectopic gestational sac and specific skills 
and expertise of the physician. Compared to the local treatment, systemic methotrexate is 
practical, easier to be administered, and less dependent from clinical skills. In combination 
with non-invasive diagnosis, systemic methotrexate offers the option of a totally non-
invasive outpatient management. Therefore, the local treatment is restricted to the cases of 
non-tubal ectopic pregnancy with live embryo (Chetty et al., 2009). 
3.2.3 Follow-up 
Patients are followed up with beta-hCG levels on days 4 and 7 after MTX injection. The 
protocol stipulates that any patient, who did not have a 15% decline in the beta-hCG levels 
between days 4 and 7, would be given an intramuscular dose of MTX (50 mg/m2). In cases 
of ectopic pregnancy with high levels of beta-hCG the use of only ultrasound-guided 
injection seems to be less effective and the combination of systemic treatment of MTX could 
improve the results. On the other hand, patients who present a decline of more than 15% in 
the beta-hCG levels in this period are monitored weekly until the beta-hCG levels are below 
5 mUI/ml. Follow up also includes clinics visits and repetition of transvaginal ultrasound if 
necessary. After approximately 3 months of treatment when the ectopic pregnancy 
disappeared at transvaginal ultrasound, a hysterosalpingography is performed. 
4. Atypical ectopic pregnancies 
The main localizations of atypical ectopic pregnancies are: cervical, caesarean scar, ovarian, 
interstitial, cornual and abdominal. This group represents less than 10% of all ectopic 
pregnancies but is associated with greater morbidity (Jourdain et al., 2003). Traditionally 
these pregnancies have been lately diagnosed and managed by open surgery. Advances in 
ultrasound technology have led to an increase in the early diagnosis of non-tubal ectopic 
pregnancies. This means that management of these rare cases of ectopic pregnancy has now 
progressed from open surgical management to the use of minimally invasive access 
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techniques and the exploration of medical and conservative treatments either alone or as 
adjuvant therapies.  
4.1 Interstitial pregnancy 
Interstitial pregnancy is an ectopic pregnancy that implanted in the interstitial portion of the 
fallopian tube. The interstitial portion is constricted, with its lumen being as narrow as 
0.1mm to 0.7 mm in diameter and 1-2 cm in length, this relatively thick section of the tube 
has a significantly greater capacity to expand before rupture than do the distal tubal 
segments (Eddy, Pauerstein, 1980). For this reason, in some cases the interstitial pregnancy 
may remain asymptomatic until 7-16 weeks of gestation, at which time rupture can result in 
important hemorrhage (Lau, Tulandi, 1999). Because of the rich vascular anastomosis of the 
uterine and the ovarian arteries in this region there can be accentuated hemorrhage. 
Therefore, early diagnosis is essential to reduce morbidity and mortality.  
Interstitial pregnancies are an uncommon form of ectopic pregnancy, account for only 2-4% 
of tubal pregnancies or approximately 1 in 2500-5000 live births (Damario et al., 2003). 
Despite their rarity, the mortality rate is as high as 2.5%, a rate that is 7 times greater than 
that of ectopic pregnancies in general (Walker, 2007). This is because the difficult diagnose 
that often presents late with rupture and hemorrhage. 
Interstitial pregnancy sometimes is incorrectly confused with cornual and angular 
pregnancies. It is important to make a distinction among these conditions because their 
behavior, management, and outcomes are different. In contrast to interstitial pregnancy, an 
angular pregnancy refers to a viable intra-uterine pregnancy that is implanted in one of the 
lateral angles of the uterine cavity, medial to the uterotubal junction. During laparoscopy, 
angular pregnancy appears as an asymmetric protuberance in one of the uterine angles, 
medial to the round ligament. On the other hand, interstitial pregnancy appears lateral to 
the round ligament. 
Cornual pregnancy refers to a pregnancy in a horn of a bicornuate uterus. The clinical 
outcome of cornual pregnancy varies greatly, depending on the size and expansile nature of 
the affected horn. 
Traditional treatments for interstitial ectopic pregnancy have ranged from exploratory 
laparotomy with cornual wedge resection to total abdominal hysterectomy. However, the 
development of high-resolution ultrasound evaluation and rapid quantitative beta-hCG 
exams has advanced the detection of interstitial gestations before rupture, which, in turn, 
has made possible more conservative treatment options for the patient whose condition is 
hemodynamically stable. Risk factors for interstitial pregnancy are tubal damage from 
previous ectopic pregnancy, previous ipsilateral or bilateral salpingectomy, conception after 
in vitro fertilization, and history of sexually transmitted disease (Tulandi, Al-Jaroudi, 2004). 
The most common symptoms of interstitial pregnancy are abdominal pain and vaginal 
bleeding in the first trimester of pregnancy. On physical examination, an asymmetric uterine 
enlargement may be palpable. Signs of acute abdomen may be elicited in cases of cornual 
rupture and hemoperitoneum; in severe cases, tachycardia and subsequent hypotension 
may be evident. Early diagnoses of interstitial pregnancies are often discovered in 
asymptomatic patients during transvaginal ultrasound that is performed in the first 
trimester. Ultrasonographic criteria for diagnosis is an empty uterine cavity, an eccentricity 
of the gestational sac, a chorionic sac separate and at least 1 cm from the lateral edge of the 
uterine cavity, and a presence of a myometrial tissue that surrounds the gestational sac with 
a thickness of ฀5 mm (Timor-Tritsch et al., 1992; Ackerman et al., 1993) (figure 3). 
www.intechopen.com
 Clinical Treatment of Unruptured Ectopic Pregnancy 
 
191 
 
A) Transversely oriented transvaginal ultrasound. B) Longitudinally oriented transvaginal ultrasound. 
Fig. 3. Interstitial ectopic pregnancy: presence of an eccentric gestational sac with 
myometrial tissue that surrounds the gestational sac with a thickness of 2 mm (Elito, 
Camano, 2010).  
Despite the advent of conservative strategies, the most appropriate technique for treatment 
of interstitial pregnancy and treatment of these patients during subsequent pregnancies 
remains controversial. Treatment options depend on the extent of uterine wall trauma, 
whether rupture has occurred and the patient’s desire for future pregnancy. If the diagnosis 
is made before rupture, minimally invasive surgery and nonsurgical treatment options can 
be used. Conservative options include methotrexate administration (local and systemic), 
expectant management and minimally invasive surgical techniques that include resection of 
the involved tube and pregnancy alone with preservation of the uterine architecture. The 
potential advantage of clinical treatment is to avoid a surgical scar on the uterus and the 
risks that are associated with surgery. 
Expectant management that has been practiced based on the natural course of many early 
EPs is a self-limiting process (Zalel et al., 1994). The inclusion criteria for this management 
are hemodynamically stable patients, beta-hCG < 1500 mUI/ml, decline of the titers of beta-
hCG in an interval of 24/48h, small interstitial pregnancy mass without fetal cardiac 
activity. The most important disadvantage of expectant management is the risk of rupture 
and associated maternal morbidity and death. 
Systemic methotrexate treatment was used for the first time in an interstitial pregnancy. In 
1982, Tanaka et al. treated successfully an interstitial pregnancy with multiple dose of 
methotrexate. Ectopic interstitial pregnancies without embryonic cardiac activity and beta-
hCG < 5000 mUI/ml should be treated with single dose of MTX 50 mg/m2 IM. Cases with 
beta-hCG > 5000 mUI/ml should be treated with multiple doses of MTX. On the other hand, 
cases with embryonic heart activity should be treated with transvaginal administration of 
MTX and KCL under sonographic guidance. The major risk for patients after treatment of 
interstitial pregnancy is uterine rupture during subsequent pregnancy and the risk of 
recurrent interstitial pregnancy. Careful prenatal with a planned cesarean delivery at term 
appears to be the safest approach (Moawad et al., 2010). 
4.2 Cervical pregnancy 
Cervical pregnancy is an atypical localization and represents less than 1% of all ectopic 
pregnancies (Pisarka, Carson, 1999). It is a high-risk condition because of the possibility of 
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severe hemorrhage. Baptiste (1953) said: “The great majority of certified obstetricians will 
never see a cervical pregnancy. The minority who do happen to encounter this complication 
will probably wish they had not”.  
The endocervix is eroded by the trophoblast that invade the fibrous cervical wall. If the 
trophoblast invasion is severe, the greater is the risk of hemorrhage.  
Some pre-disposing factors for cervical implantation described in the literature are previous 
abortion, uterine curettage, previous cesarean section, uterine fibroids, use of intrauterine 
devices and assisted reproduction with embryo transfer (Pisarka, Carson, 1999; Hsieh et al., 
2004). 
The diagnosis is based on the history of vaginal bleeding after a period of amenorrhea and 
physical exam demonstrating a cervical enlargement with vascular congestion and a thin-
walled cervix with a partially dilated external os (Figure 4).  
 
 
Fig. 4. Physical exam demonstrating a cervical enlargement with vascular congestion (Elito, 
Camano, 2010a). 
The confirmation is made by ultrasound showing an empty uterine cavity and a gestational 
sac below the level of a closed internal os within the cervix (Dialani, Levine, 2004). The main 
ultrasonographic criteria for cervical pregnancy are: empty uterine cavity or the presence of 
a pseudo gestational sac, decidual transformation of the endometrium with dense echo 
structure, diffuse uterine wall structure, hourglass uterine shape, ballooned cervical canal, 
gestational sac in the endocervix, placental tissue in the cervical canal and closed internal os 
(Hofmann et al., 1987) (figure 5).  
The classical treatment for cervical pregnancy is the hysterectomy. This modality of 
treatment compromises the reproductive future of the patient and is associated with 
significant morbidity. This procedure has a high risk of hemorrhage and trauma of the 
urinary tract because the enlargement of the cervix. The vaginal bleeding can be also treated 
with conservative surgical management such as curettage, local haemostatic sutures, 
intracervical balloon tamponade and arterial embolization (De La Veja et al., 2007; Xu et al., 
2007). However, the majority of conservative surgical treatments are ineffective and lead to 
a hysterectomy.  
The early diagnosis in asymptomatic cases has made a more conservative management of 
cervical pregnancy feasible. Medical treatment especially with methotrexate (MTX) can be 
administered systemically or locally with ultrasound guidance (Monteagudo et al., 2005; 
Mesogitis et al., 2005). The presence of embryonic heart activity is a relative contraindication 
for the systemic treatment with MTX. The predictive factors for failure in the systemic MTX  
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Fig. 5. A) Longitudinally oriented transabdominal ultrasound of cervical pregnancy 
showing an empty uterine cavity, hourglass uterine shape, placental tissue in the cervical 
canal and closed internal os. B) Longitudinally oriented transvaginal ultrasound showing an 
empty uterine cavity, hourglass uterine shape, gestational sac in the endocervix and closed 
internal os (Elito et al., 1999b). 
treatment of cervical pregnancy were described as being gestational age > 9 weeks, beta-
hCG levels > 10,000 mIU/ml, crown-rump length >10 mm, and embryonic cardiac activity 
(Bai et al., 2002). These situations have been shown to be associated with a higher risk of 
primary failure of treatment of cervical ectopic pregnancy with systemic methotrexate and 
combination therapy with intra-amniotic injection seemed to increase the chance of 
successful treatment. 
For this reason in cases with live embryo the preferable therapeutic is the ultrasound-guided 
local injection of MTX and potassium chloride (Jeng et al., 2007). KCl is injected under 
transvaginal ultrasound guidance into the embryonic heart. Following the cessation of fetal 
cardiac activity, the tip of the needle is directed into the gestational sac and gestational 
tissues and some amniotic fluid was aspirated. Then, a 1 mg/kg dose of MTX is injected into 
the gestational sac. Patients are followed up with beta-hCG levels on days 4 and 7 after MTX 
injection. The protocol stipulated that any patient who does not have a 15% decline in the 
beta-hCG levels between days 4 and 7, would be given an intramuscular dose of MTX (50 
mg/m2). On the other hand, patients who present a decline of more than 15% in the beta-
hCG levels in this period are monitored weekly until the beta-hCG levels are below 5 
mUI/ml. Follow up also include clinics visits and repeated transvaginal ultrasound if 
necessary. After approximately 3 months of treatment when the cervical pregnancy at 
transvaginal ultrasound disappears, a hysterosalpingography is performed. 
A total of 15 patients with cervical pregnancy were referred to our institution. Embryonic 
heart activity was detectable in 7 cases (46,7%), which were treated with ultrasound-guided 
injection. The assessment of the demographic characteristics of these patients demonstrated 
that 4 patients had a history of previous abortion with uterine curettage and the other 3 
cases had a previous cesarean section. The gestational age ranged from 8 to 11 weeks and 
the initial beta-hCG levels ranged from 3013 to 71199 mUI/ml. In 3 cases the titers of beta-
hCG had not declined 15% between days 4 and 7 after MTX and the patient received a single 
intramuscular dose of MTX (50 mg/m2). All patients evolved with clinical success and in 
none of the cases hysterectomy or any further intervention were required. None of cases 
needed blood transfusion. In our series in only one case there was a complication. The 
patient evolved after 7 days of the treatment with fever and the cervical examination 
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demonstrated purulent secretion. The patient was hospitalized and received intravenous 
antibiotics. She recovered without the necessity of any further intervention. Another case 
submitted to local and systemic MTX presented with stomatitis, a minor side effect of MTX. 
The interval of time for the levels of beta-hCG to become negative ranged from 2 to 12 
weeks.  The period for the regression of the cervical pregnancy at ultrasound ranged from 3 
to 14 weeks. Two patients of our series had an intrauterine pregnancy after the treatment. 
One patient had placenta previa and was submitted to a cesarean section at 37 weeks. The 
other case evaluated to a vaginal delivery at 39 weeks (Elito et al., 1999b). 
4.3 Cesarean scar pregnancy 
Implantation of a pregnancy within a cesarean scar is an uncommon form of ectopic 
pregnancy and constitutes a life-threatening condition (Fylstra et al., 2002). A cesarean scar 
pregnancy is considered to be more aggressive than placenta accreta because of its early 
invasion of the myometrium in the first trimester and the risk for uterine rupture (Seow et 
al., 2000). Rotas et al. (2006) and Ash et al. (2007) describe an increasing incidence of 
cesarean scar pregnancies of about 1:2000 pregnancies. This is likely to increase, as does the 
cesarean delivery rate.  Its true incidence, however, has not been determined because so few 
cases have been reported in the literature: only 18 cases appeared in the literature between 
1978 and 2001 (Fylstra, 2002; Seow et al., 2004). 
One of the theories to explain the occurrence of cesarean scar pregnancy is that the 
blastocyst enters into the wall through a microscopic dehiscent tract consequence of a 
cesarean or uterine surgery.  
Clinical diagnosis of an early cesarean scar pregnancy is challenge, it may occasionally be 
delayed until the uterus ruptures and the patient experiences life-threatening bleeding 
(Seow et al., 2000, 2004; Weimin and Wenqing, 2002; Maymon et al., 2004). Thus, a prompt 
and accurate diagnosis is crucial. Diagnosis should be based on history and clinical 
manifestations, such as abdominal pain and vaginal bleeding, but up to 40% of women are 
asymptomatic, and the diagnosis is made during routine ultrasound exam (Rotas et al., 
2006). 
Ultrasonography can detect an enlargement of the cesarean scar in the lower segment and a 
gestational sac that is attached to it. The most common sonographic criteria for a pregnancy 
in scar diagnosis are:  an empty uterus, an empty cervical canal, the gestational sac being 
located in the anterior part of the isthmic portion of the uterus with a diminished 
myometrial layer between the bladder and the sac and a discontinuity in the anterior wall of 
the uterus being demonstrated on a sagittal view of the uterus when the direction of the 
ultrasound beam runs through the amniotic sac (Vial et al., 2000) (Figure 6). These criteria 
assist in distinguishing this type of pregnancy from other diagnostic options, such as 
cervicoisthmic implantation, cervical pregnancy and spontaneous abortion in progress 
(Godin et al., 1997; Fylstra, 2002). Magnetic resonance imaging may also provide a more 
reliable way to identify this condition (Figure 7). 
With the limited experience on cesarean section scar pregnancies in the first trimester, it is 
difficult to conclude on the optimal management for individual cases. Management depends 
on the gestation and includes expectant management, medical and surgical treatment. The 
mode of treatment in some cases is dictated by the clinical presentation, with laparotomy 
and hysterectomy being the most appropriate treatment for the patients who present with 
haemoperitoneum and hypovolaemic shock. In a haemodynamically stable patient, two 
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Fig. 6. Longitudinally oriented transvaginal ultrasound of the uterus demonstrating an 
empty uterus, an empty cervical canal, the gestational sac being located in the anterior part 
of the isthmic portion of the uterus with a diminished myometrial layer and a discontinuity 
in the anterior wall of the uterus (Elito, Camano, 2010a). 
 
 
 
 
 
 
 
 
 
 
Fig. 7. Magnetic resonance imaging of the same case (Elito, Camano, 2010a). 
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principle management options may be considered, clinical or surgical, both aimed to 
eliminate the gestational sac and retain the patient’s fertility. In cases where the diagnosis is 
made early and the patient is haemodynamically stable, assessment of the thickness of the 
anterior uterine wall is essential because a non-surgical procedure is the most appropriate 
option when the trophoblast reaches the vesico-uterine space on the bladder wall, thereby 
obviating an extended operation. There are few reported cases of cesarean section scar 
pregnancies managed expectantly in the literature. Two of these required additional 
treatment with methotrexate (Godin et al., 1997; Jurkovic et al., 2003) and two had 
emergency hysterectomies (Herman et al., 1995; Jurkovic et al., 2003). Expectant 
management does not therefore seem to be an appropriate choice, with the majority of cases 
reported requiring medical or surgical intervention. 
Medical treatment consists of methotrexate administered systemically, locally or combined. 
Medical management with local injection of methotrexate has been more successful, with 
success rates of 70–80% when used as the initial treatment option (Jurkovic et al., 2003). This 
involves the direct injection of methotrexate into the pregnancy, performed transvaginally 
under ultrasound guidance. Local injections of potassium chloride have also been reported 
and were used prior to local methotrexate where embryonic cardiac activity was detected. 
Methotrexate has also been used systemically. The risk of cesarean scar rupture and heavy 
bleeding may occur following medical treatment. This has led some authors to propose that 
the medical approach should be combined with either bilateral uterine artery embolization 
or vasopressin intracervical injection combined with 18 Foley catheter balloon tamponade 
(Chuang et al., 2003), thus avoiding such complications (Ghezzi et al., 2002). 
4.4 Ovarian pregnancy 
Ovarian pregnancy represents the most common type of atypical localization of ectopic 
pregnancy.  
In primary ovarian pregnancy the ovum is not guided into the tube but is fertilized in the 
peritoneal cavity and then implants onto the ovary. It causes the same symptoms as a tubal 
pregnancy and severe internal bleeding will eventually occur. In the secondary type, there is 
a tubal abortion with secondary implantation of the embryo on the tubal surface. Ovarian 
pregnancy is a rare form of ectopic gestation with estimates of frequency ranging from 1 in 
2100 to 1 in 7000 pregnancies (Hage et al., 1994). It represents 0.5-3% of all ectopic 
pregnancies (Bouyer, Coste, 2002). Risk factors include previous pelvic inflammatory 
disease, IUD use, endometriosis, and assisted reproductive technologies (Marret et al., 1997). 
Spiegelberg (1878) suggested four criteria to diagnose an ovarian pregnancy: the fallopian 
tube with its fimbria should be intact and separate from the ovary, the gestational sac 
should occupy the normal position of the ovary, the gestational sac should be connected to 
the uterus by the ovarian ligament and ovarian tissue must be present in the specimen 
attached to the gestational sac. 
The diagnosis is difficult and a continuous challenge to the gynecologist. The presentation of 
ovarian pregnancy is commonly indistinguishable from tubal pregnancy, except for the 
predisposition to early rupture. The diagnosis of an ovarian ectopic pregnancy is seldom 
made before surgery. Transvaginal ultrasound is an important tool in the diagnosis of this 
condition. At ultrasound ovarian pregnancies show as a cyst with a wide echogenic outside 
ring. A yolk sac or embryo is less commonly seen and the appearance of the sac contents 
tends to lag in comparison to gestational age. However, it can be mistaken for a 
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hemorrhagic corpus luteum or ovarian cyst. Misdiagnoses range from 35% (Hallat, 1982) to 
75% (Herbertsson et al., 1987). Thick-walled ovarian cysts in the patient with an empty 
uterus and a serum beta-hCG level above the discriminatory zone should be investigated 
with particular care (Bontis et al., 1997). Most commonly symptoms are abdominal pain and 
light vaginal bleeding and diagnostic laparoscopy is often required to make the diagnosis of 
an ovarian pregnancy which is later confirmed by histological examination of the specimen 
(De Seta et al., 2001). Intraoperatively, ovarian ectopic pregnancies often resemble 
haemorrhagic cysts. 
With early diagnosis laparoscopic surgery is the main method of treatment for ovarian 
ectopic pregnancies. Early detection of an ovarian pregnancy prior to rupture of the 
gestational sac and to onset of active bleeding permits laparoscopic surgery and removal of 
the ectopic pregnancy without excessive removal of healthy ovarian tissue (figure 8). 
 
 
Fig. 8. Laparoscopic conservative surgery with removal of trophoblast tissue of the ovarian 
pregnancy (Elito, Camano, 2010b). 
The medical treatment with methotrexate could be used in selected patients. It avoids 
surgical complications such as intraoperative hemorrhage, oophorectomy and pelvic 
adhesions. 
Systemic methotrexate has been successfully used to treat ovarian ectopic pregnancy. There 
may be a place for medical management of carefully selected cases of ovarian ectopic 
pregnancy but selection criteria are not defined. Methotrexate may also be useful in the 
treatment of persistent trophoblastic tissue after laparoscopy (Einenkel et al., 2000). Though, 
if the initial diagnosis of an ectopic pregnancy is made during laparoscopy, it is preferable to 
remove it at the procedure. Nowadays, with early diagnosis and improvement of surgical 
techniques the ovarian tissue is preserved with minimal pelvic adhesions. 
In the majority of cases ovarian pregnancies are diagnosed definitively at the time of 
surgical exploration. Therefore, MTX is not a first- line treatment for this condition. 
4.5 Abdominal pregnancy 
Abdominal pregnancy is one of the rarest form of ectopic pregnancy at 1.3% (Bouyer, Coste, 
2002). It is described as primary or secondary where a tubal pregnancy aborts through the 
fimbrial end and implants in the peritoneal cavity. The vast majority of abdominal 
pregnancies are secondary. Most abdominal pregnancies are confined to the lower abdomen 
limited to the adnexa or the broad ligament (Holzhacker et al., 2008). However, abdominal 
pregnancies have been reported on the spleen, liver and diafragm. Early diagnosis is very 
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important in this situation. Treatment is easier in the first trimester of pregnancy. Clinical 
signs of early abdominal pregnancy are similar to those of other ectopic pregnancies. 
However, in advanced abdominal pregnancy frequent symptoms are abdominal pain, 
nausea, vomiting, diarrhea, painful fetal movement and fetal movements high in the 
abdomen. Ultrasound is the diagnostic procedure of choice. The following ultrasound 
criteria have been suggested as being diagnostic: an empty uterus, absence of both an 
evident dilated tube and a complex adnexal mass, a gestational cavity surrounded by loops 
of bowel and separated by peritoneum, a wide mobility similar to fluctuation of the sac 
particularly evident with pressure of the transvaginal probe toward the posterior cul-de-sac. 
MRI may also provide a more reliable way to identify this condition (figure 9). Early 
diagnosis allows for optimization of surgical conditions, including pre-operative arterial 
embolization, availability of blood products, bowel prepare and multidisciplinary surgery 
team. The traditional management involves a laparotomy with removal of the fetus with or 
without placental tissue (Ayinde et al., 2005). Recently, there have been several reports of 
laparoscopic management (Shaw et al., 2007). One of the problems associated with the 
removal of abdominal pregnancies after the first trimester is the risk of massive blood loss 
from the placental bed. Adjuvant treatment with methotrexate alongside selective arterial 
embolization has been suggested to control this (Oki et al., 2008). There are also case reports 
of early abdominal pregnancies being treated successfully with systemic methotrexate and 
ultrasound guided injection of potassium chloride, leading to reabsorption of the products 
of conception without the need for further surgery (Mitra, Le Quire, 2003). 
 
 
Fig. 9. MRI of advanced intraligamentar abdominal pregnancy (Holzhacker et al., 2008).. 
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4.6 Heterotopic pregnancy 
Heterotopic pregnancy is defined by coexisting intrauterine and extrauterine pregnancies 
(figure 10). The increase of assisted reproduction resulted in a rise of heterotopic pregnancy. 
Nowadays approximately 1% of pregnancies resulting from assisted reproduction are 
heterotopic pregnancies. Unfortunately, approximately 50% of heterotopic pregnancies 
present symptoms of tubal rupture. Surgery is usually required and MTX is contraindicated 
(Chin et al., 2004; Fernandez et al., 2004). In cases of heterotopic pregnancy with an association 
of intra-uterine pregnancy and non-tubal pregnancy with embryonic cardiac activity, an 
alternative treatment could be local injection of KCL under ultrasound guidance. One 
important drawback for medical treatment in heterotopic pregnancy is the follow-up. Usually, 
the follow-up after medical treatment is made by the evaluation of the levels of beta-hCG. In 
heterotopic pregnancies this parameter cannot be used and ultrasound is a poor method to 
follow the patient. Therefore, medical treatment of heterotopic pregnancy should be restricted 
to cases with an association of atypical localization and intrauterine pregnancy, because in this 
situation the surgical treatment of choice is the hysterectomy. Other uncommon presentation 
of heterotopic pregnancy is the association of two extra-uterine pregnancies, such as tubal 
pregnancy and interstitial pregnancy or both tubal pregnancies. In these cases of heterotopic 
pregnancies without a viable intrauterine pregnancy medical treatment can be performed 
following the same rules of other ectopic pregnancies. 
 
 
Fig. 10. Transvaginal ultrasound of heterotopic pregnancy showing at left side the tubal ring 
pregnancy and at right side the intrauterine pregnancy, between both the ovarian with two 
corpus luteum (Elito, Camano, 2010a). 
4.7 Management in atypical ectopic pregnancies 
There are many different approaches to the management of unusual ectopic pregnancies. 
Cases with embryonic cardiac activity should be treated with transvaginal administration of 
MTX and KCL under sonographic guidance. Ectopic pregnancies without embryonic cardiac 
activity and beta-hCG < 5000 mUI/ml should be treated with single dose of MTX 50 mg/m2 
IM. Cases with beta-hCG > 5000 mUI/ml should be treated with multiple doses of MTX 
(Elito et al., 2008). It seems reasonable to treat some of these pregnancies with a combination 
of local and systemic MTX, in particular cases with high levels of beta-hCG. Adjunctive 
techniques for controlling hemorrhage (cervical cerclage, uterine artery embolization) 
should also be considered and a plan made for urgent assistance. 
Surgery remains the main way for treatment of ovarian and abdominal ectopic pregnancies 
(Holzhacker et al., 2008). 
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5. Reproductive future 
5.1 Hysterosalpingography  
The fertility outcome of patients with unruptured EP treated conservatively with either 
MTX or expectant management can be evaluated indirectly through the 
hysterosalpingography (HSG) and directly by means of future pregnancy (Debby et al., 
2000; Elito et al., 2006). The HSG represents important diagnosis methods after the treatment 
of EP, in spite of the inconveniences and doubts about the interpretation of this examination. 
The tubal patency after MTX is 84% and after expectant management is 78% (Elito et al., 
2005a). This high rate of radiologically normal tubes after clinical treatment proves that the 
spontaneous regression of EP does not result in an increased harm or damage to the tube. 
However, the radiologically normal findings show nothing about the tubal function, when a 
disturbance can also be the cause of EP. On the other hand, if the results of HSG 
demonstrate obstruction of the tubes, the possibility of a spontaneous pregnancy will be 
reduced and should be treated with in vitro fertilization. The tubal obstruction is increased 
in cases with high beta-hCG levels (Elito et al., 2005b). The explanation for higher incidence 
of tubal obstruction is that in patients with higher levels of beta-hCG there is more invasion 
of the trophoblast tissue at the tube’s serosa, what increases the damage to the tube.  
5.2 Future pregnancy 
After medical treatment 65% of patients who attempted subsequent pregnancies succeeded, 
and the incidence of recurrent ectopic pregnancy was relatively low at 13% (Stovall et al., 
1989; Lipscomb et al., 2000). Systemic MTX in a single-dose regimen compared with 
laparoscopic salpingostomy of four trials (Fernandez et al., 1998; Saraj et al., 1998; Sowter et 
al., 2001; El-Sherbiny et al., 2003), involving 265 haemodynamically stable women with a 
small unruptured tubal EP, showed no significant differences in the number of IUPs (RR 
1.01, 95% CI 0.66–1.54), whereas there was a non-significant trend towards a lower incidence 
of repeat EPs (RR 0.63, 95% CI 0.14–2.77) (Mol et al., 2008). Systemic MTX in a fixed multiple 
dose regimen compared with laparoscopic salpingostomy observed that fertility outcome 
was no significant different for IUP (RR 0.88, 95% CI 0.49–1.60) as well as for repeat EP (RR 
0.88, 95% CI 0.21–3.67) (Dias Pereira et al., 1999). 
6. Cost analysis 
Serial serum beta-hCG measurements and transvaginal ultrasound examination can provide 
early diagnosis of most ectopic pregnancies allowing medical treatment with methotrexate. 
Approximately 40% of women diagnosed with ectopic pregnancy are candidates for medical 
management (Barnhart et al., 2003), and 90% of those can be treated successfully without 
surgery (Lipscomb et al., 2000). Whereas the costs of surgery and outpatient medical 
management vary widely, many cost-effectiveness analyses have favored MTX therapy. 
Systemic MTX in a single-dose regimen resulted in significant savings in direct costs 
compared with laparoscopic surgery: mean direct costs per patient were € 756 and € 1585, 
respectively, with a mean difference of € 829 (95% CI 599–1060). Furthermore, systemic MTX 
resulted in significant savings in indirect costs: mean indirect costs per patient were € 587 
and € 977, respectively, with a mean difference of € 390 (95% CI 142–638). However, in 
women with initial serum hCG concentrations >1500 IU/l the difference in indirect costs 
was lost due to the prolonged follow-up and a higher rate of surgical re-interventions 
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(Sowter et al., 2001). Therefore, medical treatment is less expensive than surgery, except in 
cases with higher levels of beta-hCG (Sowter et al., 2001).  
7. Conclusion 
The early non-invasive diagnosis of ectopic pregnancy, before there is tubal rupture, can be 
made through transvaginal ultrasonography and with the dosage of the beta-fraction of the 
chorionic gonadotrophin. After the diagnosis, range of treatments may be used. Either a 
surgical intervention or a clinical treatment (expectant management or methotrexate 
therapy) may be taken into consideration.  Expectant management should be indicated in 
cases of decline in the beta-hCG titers within 48 hours before the treatment, and when the 
initial titers are under 1,500 mUI/mL. The use of methotrexate (MTX) is a safe clinical 
procedure and in some cases could be indicated as the first option for treatment. The main 
criteria for MTX indication are hemodynamic stability, beta-hCG <5,000 mUI/mL, adnexal 
mass <3,5 cm, and no embryonic cardiac activity. It is preferable to administer a single 
intramuscular dose MTX (50 mg/m2) because it is easier, more practical and with less side 
effects (diagram 1). Protocol with multiple doses should be restricted for the cases with 
atypical localization (interstitial, cervical, caesarean section scar and ovarian) with values of 
beta-hCG >5,000 mUI/mL and no fetal heart activity. Indication for local treatment with an 
injection of MTX (1 mg/kg) and KCl guided by transvaginal ultrasonography should occur 
in cases of embryonic cardiac activity but with an atypical localization (Elito et al., 2008).  
 
 
Diagram 1. Recommendation for Treatment of Unruptured Tubal Pregnancy (Elito et al., 
2008) 
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